关注蛋白激酶抑制剂的口服生物利用度:评估药物相互作用程度与改进临床实践的关键
蛋白激酶抑制剂均经CYP酶代谢,多数以CYP3A4为主,但口服生物利用度差异显著,如伊马替尼接近100%而伊布替尼平均仅3%。口服生物利用度越低,个体间药代动力学变异越大,CYP3A4抑制剂或诱导剂导致的药物相互作用影响也越强。本文阐述上述药代动力学概念,并讨论食物影响、血浆蛋白结合相关相互作用及治疗药物监测的临床价值。
要点
- 蛋白激酶抑制剂口服生物利用度差异大,伊马替尼近100%,伊布替尼平均3%。
- 口服生物利用度越低,个体间药代动力学变异越大,药物暴露差异越明显。
- 低口服生物利用度药物的CYP3A4抑制剂或诱导剂相互作用影响更大。
核心结论
- 蛋白激酶抑制剂的口服生物利用度是评估药物相互作用程度和指导临床实践的关键药代动力学参数。
研究设计与样本
- 本文为综述,围绕蛋白激酶抑制剂的药代动力学特征、药物相互作用及临床实践应用进行阐述。
主要发现
- 蛋白激酶抑制剂均经多个CYP酶代谢,多数以CYP3A4为主要代谢途径,但口服生物利用度各异。
- 伊马替尼口服生物利用度估计接近100%,伊布替尼因肝脏首过效应强平均仅3%。
- 口服生物利用度越小,个体间药代动力学变异越大,吸收程度差异是药物暴露差异的额外原因。
- CYP3A4抑制剂和诱导剂对低口服生物利用度蛋白激酶抑制剂的相互作用影响远大于高生物利用度药物。
临床怎么用
- 临床应关注蛋白激酶抑制剂的口服生物利用度,以评估CYP3A4介导药物相互作用的潜在程度。
- 对低口服生物利用度药物,需更警惕CYP3A4抑制剂或诱导剂导致的暴露变化。
- 治疗药物监测可用于管理蛋白激酶抑制剂的个体间药代动力学变异和药物相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Protein kinase inhibitors share pharmacokinetic (PK) pathways among themselves. They are all metabolized by several cytochromes P450 (CYP). For most of them, CYP3A4 is the predominant metabolic pathway. However, their oral bioavailability differs. For example, the oral bioavailability of imatinib has been estimated at nearly 100%, but that of ibrutinib averages 3% due to its high hepatic first-pass effect. Overall, the smaller the oral bioavailability, the larger its interindividual PK variability. Indeed, for drugs with low oral bioavailability, the extent of their absorption is an additional cause (along with elimination variability) of differences in drug exposure among patients. The impact of drug-drug interaction (DDI) also differs between drugs with low or high oral bioavailability. We describe and explain why the impact of CYP3A4 inhibitors and inducers is much greater for protein kinase inhibitors with low oral bioavailability. The effect of food on protein kinase inhibitors and DDIs corresponding to plasma protein binding will also be considered. Finally, the benefits of these concepts in clinical practice (including therapeutic drug monitoring) will be discussed. Overall, our main objective was to apply fundamental PK concepts to understanding the main clinical issues of these oral anticancer drugs.
引用
- Le Louedec F, Puisset F, Chatelut E, et al. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clin Pharmacokinet. 2023. PMID: 36631685. doi:10.1007/s40262-022-01200-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。